10-K: Quanome Technologies Reports FY2026 Results, Faces Internal Control Challenges

Quanome Technologies, Inc. (QNME) disclosed its fiscal year 2026 results, highlighting substantial revenue growth in its pharmaceutical distribution segment and strategic advancements in AI and quantum technologies, while also reporting material weaknesses in internal controls and ongoing Nasdaq listing compliance efforts.

Summary

• Quanome Technologies reported revenue of $5.85 million for the fiscal year ended June 30, 2026, an increase of 111.8% from $2.76 million in the prior year, primarily driven by its pharmaceutical distribution business.
• The company experienced a net loss of $9.48 million for FY2026, compared to a net loss of $5.25 million in FY2025.
• Significant operating expenses included a $2.86 million write-off of a supplier advance and a $2.26 million provision for expected credit loss on a loan receivable.
• The company has identified material weaknesses in its internal control over financial reporting, specifically regarding segregation of duties, risk assessment, and insufficient written policies and procedures.
• Quanome is actively pursuing new strategic initiatives in AI compute capacity and managed inference services, and quantum-related technologies, though these have not yet generated revenue.
• The company received a second notice from Nasdaq regarding its minimum bid price requirement and has until January 4, 2027, to regain compliance, potentially through a reverse stock split.
• The disposal of the ABL Chicago business was completed on February 12, 2026, resulting in a gain on sale of $2.56 million and reclassification of its results as discontinued operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to significant net losses, material weaknesses in internal controls, and ongoing Nasdaq listing compliance issues, despite revenue growth and strategic shifts.

Positives

• Revenue from continuing pharmaceutical operations increased by 111.8% to $5.85 million for the year ended June 30, 2026, from $2.76 million in the prior year.
• Gross profit margin improved slightly from 56.1% to 56.7% due to changes in supplier incentives and purchase rebates.
• The company has initiated strategic efforts in AI compute capacity and managed inference services, and quantum-related technologies, indicating a forward-looking approach.
• The disposal of the ABL Chicago business resulted in a gain of $2.56 million.
• Working capital surplus improved significantly from $0.61 million to $6.53 million as of June 30, 2026.

Negatives

• The company reported a net loss of $9.48 million for FY2026, an increase from $5.25 million in FY2025.
• Operating expenses significantly increased, including a $2.86 million write-off of a supplier advance and a $2.26 million provision for expected credit loss on a loan receivable.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties, risk assessment, and insufficient written policies and procedures.
• The company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting if compliance is not regained by January 4, 2027.
• The company's financial statements include a going concern warning due to recurring net losses and negative cash flows from operations.
• The company has not yet generated revenue from its new AI and quantum technology initiatives.

Risks

• The company's pharmaceutical distribution business depends on relationships with manufacturers and suppliers, and interruptions in product supply could adversely affect revenue and profitability.
• The pharmaceutical distribution industry in China is competitive, and pricing pressure and changes in customer demand could negatively impact results.
• Expansion into new business areas like AI and quantum technologies carries significant operational, regulatory, and execution risks, with no assurance of success or revenue generation.
• The company's ability to control costs is critical, and increasing operating expenses without corresponding revenue growth could materially affect financial condition.
• Failure to obtain or maintain requisite regulatory approvals, licenses, and permits for its business operations could have a material adverse effect.
• The company's AI compute services business is at an early stage and depends on the availability, performance, and cost of specialized computing infrastructure, which may be subject to supply constraints and rapid technological change.
• Evolving export control, sanctions, data protection, and cybersecurity regulations could restrict the company's ability to provide AI computing services.
• The company faces risks related to its PRC operations, including significant government oversight, potential regulatory changes, and restrictions on cash transfers and dividend distributions.

Future Outlook

The company is strategically repositioning towards quantum-related technologies and AI compute capacity, with these initiatives in development and evaluation stages and not yet generating revenue. The pharmaceutical distribution business is expected to continue, with efforts to capture growth opportunities in response to industry developments. The company faces ongoing challenges related to Nasdaq listing compliance and internal control remediation.

Management Comments

• The Company is evaluating opportunities to reposition its business from traditional pharmaceutical distribution services toward quantum-related technologies and applications, including those involving quantum computing, artificial intelligence, advanced simulation and intelligent systems.
• Beginning in September 2026, the Company, through its indirectly wholly owned subsidiary, XDT Infrastructure I, LLC, commenced activities relating to the provision of artificial intelligence compute capacity and managed inference services.
• We are taking steps to remediate these material weaknesses, including hiring additional accounting personnel with U.S. GAAP and SEC reporting experience, implementing formal period-end financial reporting procedures and controls, and enhancing our internal audit function and Sarbanes-Oxley compliance processes.

Industry Context

StockSavvy.ai notes that Quanome Technologies is navigating a significant strategic pivot, moving from a traditional pharmaceutical distribution model in China to emerging technology sectors like AI and quantum computing. This diversification is common in the tech landscape but carries substantial development and market adoption risks. The company's continued reliance on pharmaceutical distribution provides a revenue base, but the future growth hinges on the success of its nascent technology ventures.

Comparison to Industry Standards

• The company's revenue growth of 111.8% in its pharmaceutical distribution segment is strong, but it operates in a highly competitive Chinese market where larger players often have greater scale and purchasing power.
• The significant net loss and material weaknesses in internal controls are concerning and place the company below industry standards for established public companies, particularly those listed on Nasdaq.
• The company's strategic shift into AI and quantum computing places it in a highly dynamic and capital-intensive sector, where established players like NVIDIA, IBM, and Google are making significant investments. Quanome's early-stage efforts are not directly comparable to these leaders.
• The ongoing Nasdaq listing compliance issues (minimum bid price) are a significant concern and deviate from the stability expected of companies on major exchanges.

Corporate Governance

Legal Proceedings

• The company is not currently a party to, nor aware of, any legal proceedings that are likely to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• The company had a balance due to its CEO, Yang Li, of $220,220 as of June 30, 2026, representing expenses paid on behalf of the company.
• Prior to the disposal of ABL Chicago, there were numerous transactions with related parties including revenue from services, cost of revenue charged by related parties, and rental income.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings and potential delisting from Nasdaq if compliance issues are not resolved.
• Employees may be impacted by the company's strategic shifts and the ongoing efforts to improve internal controls.
• Creditors and lenders may face increased risk due to the company's net losses and going concern uncertainties, although the company has improved its working capital position.

Next Steps

• Remediate material weaknesses in internal control over financial reporting.
• Regain compliance with Nasdaq's minimum bid price requirement by January 4, 2027.
• Continue development and evaluation of AI compute capacity and quantum-related technology initiatives.
• Pursue opportunities to expand and diversify business operations.
• Monitor and adapt to evolving PRC regulations concerning data security, cybersecurity, and foreign exchange.

Key Dates

Recommendation

The company shows strong revenue growth in its core pharmaceutical distribution business and is making strategic moves into high-growth technology sectors. However, significant net losses, material weaknesses in internal controls, and ongoing Nasdaq listing compliance issues present substantial risks. A hold recommendation reflects the potential upside from new ventures balanced against the considerable financial and operational challenges.

Keywords

Quanome Technologies, Form 10-K, Annual Report, Pharmaceutical Distribution, AI Compute Capacity, Quantum Technologies, Financial Results, Internal Controls